{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:59:59Z","timestamp":1791932399244,"version":"4.3.4"},"reference-count":36,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Coalition for Epidemic Preparedness Innovations","award":["HHSN272201700077C"],"award-info":[{"award-number":["HHSN272201700077C"]}]},{"name":"National Institutes of Allergy and Infectious Diseases\/National Institutes of Health","award":["HHSN272201700077C"],"award-info":[{"award-number":["HHSN272201700077C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>There are currently no prophylactic vaccines licensed to protect against Lassa fever caused by Lassa virus (LASV) infection. The Emergent BioSolutions (EBS) vaccine candidate, EBS-LASV, is being developed for the prevention of Lassa fever. EBS-LASV is a live-attenuated recombinant Vesicular Stomatitis Virus (rVSV)-vectored vaccine encoding the surface glycoprotein complex (GPC) from LASV and has two attenuating vector modifications: a gene shuffle of the VSV N gene and a deletion of the VSV G gene. Preclinical studies were performed to evaluate EBS-LASV\u2019s neurovirulence potential following intracranial (IC) injection and to determine the biodistribution and vector replication following intramuscular (IM) inoculation in mice. In addition, the potential EBS-LASV toxicity was assessed using repeated-dose IM EBS-LASV administration to rabbits. All mice receiving the IC injection of EBS-LASV survived, while mice administered the unattenuated control vector did not. The vaccine was only detected in the muscle at the injection site, draining lymph nodes, and the spleen over the first week following IM EBS-LASV injection in mice, with no detectable plasma viremia. No toxicity was observed in rabbits receiving a three-dose regimen of EBS-LASV. These studies demonstrate that EBS-LASV is safe when administered to animals and supported a first-in-human dose-escalation, safety, and immunogenicity clinical study.<\/jats:p>","DOI":"10.3390\/vaccines12080858","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T10:34:43Z","timestamp":1722422083000},"page":"858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical Safety Assessment of the EBS-LASV Vaccine Candidate against Lassa Fever Virus"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5441-2882","authenticated-orcid":false,"given":"Demetrius","family":"Matassov","sequence":"first","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Evans","family":"DeWald","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hamm","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Nowak","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl S.","family":"Gerardi","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa E.","family":"Latham","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amara","family":"Luckay","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Chen","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry","family":"Shearer","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wynn","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Eldridge","sequence":"additional","affiliation":[{"name":"Auro Vaccines LLC, Pearl River, NY 10965, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-5388","authenticated-orcid":false,"given":"Kelly","family":"Warfield","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Spurgers","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc., Gaithersburg, MA 20879, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"j2986","DOI":"10.1136\/bmj.j2986","article-title":"Lassa fever","volume":"358","author":"Houlihan","year":"2017","journal-title":"BMJ"},{"key":"ref_2","unstructured":"WHO (2020, August 20). Geographic Distribution of Lassa Fever in West African Affected Countries (1969 to 2018): World Health Organization. Available online: https:\/\/www.who.int\/health-topics\/lassa-fever\/#tab=tab_1."},{"key":"ref_3","unstructured":"CDC (2020, August 20). Lassa Fever: Centers for Disease Control and Prevention (United States of America), Content Source: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). 31 January 2019, Available online: https:\/\/www.cdc.gov\/vhf\/lassa\/index.html."},{"key":"ref_4","unstructured":"WHO (2017, August 20). Lassa Fever World Health Organization. 31 July 2017. Available online: https:\/\/www.who.int\/health-topics\/lassa-fever#tab=tab_1."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","article-title":"A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy","volume":"297","author":"Price","year":"1988","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"ref_7","unstructured":"NIAID (2024, July 24). Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults ClinicalTrials.gov: National Institute of Allergy and Infectious Diseases (NIAID), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01438606."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1128\/JVI.01911-06","article-title":"Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations","volume":"81","author":"Clarke","year":"2007","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: A randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Clarke","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ofv082","DOI":"10.1093\/ofid\/ofv082","article-title":"First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)","volume":"2","author":"Fuchs","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wolf, J., Jannat, R., Dubey, S., Troth, S., Onorato, M.T., Coller, B.-A., Hanson, M.E., and Simon, J.K. (2021). Development of Pandemic Vaccines: ERVEBO Case Study. Vaccines, 9.","DOI":"10.3390\/vaccines9030190"},{"key":"ref_12","unstructured":"FDA (2024, July 24). Package Insert\u2014ERVEBO\u00ae 2019, Available online: https:\/\/www.fda.gov\/media\/133748\/download."},{"key":"ref_13","unstructured":"EMA (2024, July 24). ERVEBO\u00ae Ebola Zaire Vaccine, (rVSV\u0394G-ZEBOV-GP, Live). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ervebo."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11540","DOI":"10.1128\/JVI.02558-08","article-title":"Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain","volume":"83","author":"Ozduman","year":"2009","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1354\/vp.40-5-512","article-title":"Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis","volume":"40","author":"Sur","year":"2003","journal-title":"Vet. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1128\/JVI.03441-13","article-title":"Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates","volume":"88","author":"Clarke","year":"2014","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1073\/pnas.95.7.3501","article-title":"Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus","volume":"95","author":"Wertz","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Monath, T.P., Nichols, R., Tussey, L., Scappaticci, K., Pullano, T.G., Whiteman, M.D., Vasilakis, N., Rossi, S.L., Campos, R.K., and Azar, S.R. (2002). Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010658"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2008","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coviro.2019.07.005","article-title":"Animal models for Lassa virus infection","volume":"37","author":"Feldmann","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1128\/JVI.77.10.5740-5748.2003","article-title":"Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neurolapathogenesis in mice","volume":"77","author":"Flanagan","year":"2003","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1128\/jvi.65.9.4950-4958.1991","article-title":"Murine infection by vesicular stomatitis virus: Initial characterization of the H-2d system","volume":"65","author":"Forger","year":"1991","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.67.2.201","article-title":"Influence of Host Factors on Neuroinvasiveness of Vesicular Stomatitis Virus: Iii. Effect of Age and Pathway of Infection on the Character and Localization of Lesions in the Central Nervous System","volume":"67","author":"Sabin","year":"1938","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0042-6822(89)90287-0","article-title":"Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses","volume":"168","author":"Auperin","year":"1989","journal-title":"Virology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J. Virol. Methods"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/JVI.02525-06","article-title":"Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: Vector spread correlates with induction of immune responses and persistence of genomic RNA","volume":"81","author":"Simon","year":"2007","journal-title":"J. Virol."},{"key":"ref_28","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2010). Note for Guidance on Repeated Dose Toxicity, Committee for Medicinal Products for Human Use (CHMP). CPMP\/SWP\/1042\/99corr."},{"key":"ref_29","unstructured":"ICH Harmonised Tripartite Guideline M3 (R2) (2024, July 24). Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals and Marketing Authorization for Pharmaceuticals: FDA Rockville Maryland January 2010, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization."},{"key":"ref_30","unstructured":"National Research Council (2011). Guide for the Care and Use of Laboratory Animals, The National Academies Press. (In English)."},{"key":"ref_31","unstructured":"Canadian Council on Animal Care (CCAC) (2020). Guide to the Care and Use of Experimental Animals, CCAC. [2nd ed.]."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Green, M.D., and Hussain Al-Humadi, N. (2024, July 24). Preclinical Toxicology of Vaccines, A Comprehensive Guide to Toxicology in Preclinical Drug Development, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7161391\/.","DOI":"10.1016\/B978-0-323-85704-8.00003-7"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.vaccine.2009.03.006","article-title":"In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation","volume":"27","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jviromet.2009.11.023","article-title":"Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression","volume":"164","author":"Witko","year":"2010","journal-title":"J. Virol. Methods"},{"key":"ref_35","unstructured":"(2014). WHO Guidelines on Nonclinical Evaluation of Vaccines, World Health Organization. Available online: https:\/\/www.who.int\/publications\/m\/item\/TRS-987-annex2."},{"key":"ref_36","unstructured":"Pan African Clinical Trials Registry (2021, August 17). A Study to Assess a New Lassa Virus Vaccine in Healthy Volunteers. Available online: https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=14618."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:26:43Z","timestamp":1760110003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["vaccines12080858"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12080858","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}